PARP1 and ovarian cancer: Currently, the FDA has approved four PARP inhibiting drugs (olaparib, rucaparib, talazoparib, and niraparib) to ensure the treatment of breast carcinoma (having detrimental BRCA mutation) along with advanced ovarian cancer (Kim et al., 2021; Min and Im, 2020).